ClinicalTrials.gg
Not yet recruitingNCT07784335Updated Aug 25, 2026

Pharmacokinetics of Huperzine A Oral Solution in Healthy Participants

A Phase 1 interventional study of Huperzine A Oral Solution and Placebo in Healhty, sponsored by Wanbangde Pharmaceutical Group Co., LTD. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-25.

Sponsored by Wanbangde Pharmaceutical Group Co., LTD · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

In this study, 4 dose groups are planned: Group 1 (0.22 mg, QD), Group 2 (0.22 mg, BID), Group 3 (0.44 mg, QD), and Group 4 (0.44 mg, BID). Ten healthy study participants will be enrolled in each dose group, and randomized to the investigational drug group or the placebo group in a 4:1 ratio (i.e., 8 study participants in the investigational drug group and 2 study participants in the placebo group). An appropriate gender ratio will be ensured within each dose group.

02

Conditions studied

  • Healhty
03

In context

Lead sponsor

Wanbangde Pharmaceutical Group Co., LTD is the lead sponsor of 8 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants must provide written prior to the study, with full understanding of the study's objectives, procedures, and potential adverse reactions;
  2. Participants must be able to communicate effectively with the investigators and comply with the protocol requirements throughout the study.
  3. Healthy male or female, aged 18 to 55 years (inclusive);
  4. (BMI) range: 19.0 to 26.0 kg/m2 [BMI = body weight/height2 (kg/m2)] (inclusive); male weight ≥50 kg, female weight ≥45 kg.

Exclusion criteria

Exclusion Criteria:

  1. History of allergy to huperzine A or any drug component (pharmaceutical-grade sodium benzoate); history of allergies to two or more drugs, foods, etc.;
  2. History or suspected history of gastrointestinal bleeding, or conditions posing a risk of gastrointestinal bleeding (e.g., peptic ulcer, inflammatory bowel disease, diverticula, hemorrhoids, colonic polyps, etc.);
  3. Currently diagnosed with or suspected of having epilepsy, angina pectoris, bronchial asthma, mechanical intestinal obstruction, renal insufficiency, or urinary tract obstruction;
  4. Currently diagnosed with or suspected of having other serious diseases that, in the judgment of the investigator, make the individual unsuitable for participation in the study. These may include, but are not limited to, diseases related to the respiratory, circulatory, digestive, hematologic, endocrine, immune, integumentary, neuropsychiatric, or otorhinolaryngologic systems;
  5. Underwent major surgery within 180 days prior to the first dose or plans to undergo surgery during the study period;
  6. Participants with significant abnormalities in vital signs (normal reference ranges for vital signs (including critical values): body temperature (aural) 35.9 ℃ to 37.4 ℃, sitting systolic blood pressure 90 mmHg to 140 mmHg, sitting diastolic blood pressure 60 mmHg to 90 mmHg, sitting pulse 50 to 100 beats per minute, respiratory rate 12 to 20 breaths per minute), physical examination, ( corrected for heart rate using Fridericia's formula (QTcF) >450 ms (males) or >460 ms (females)), or laboratory test results, and judged by the investigator as unsuitable for participation in this study;
  7. History of , , , or syphilis and/or those with one or more abnormal results in infectious disease screening (anti-HIV antibody, hepatitis B surface antigen, anti-hepatitis C virus antibody, anti-Treponema pallidum antibody) that are considered by the investigator;
  8. Study participants who have experienced blood loss (excluding normal physiological blood loss in females) or donated ≥200 mL of blood or donated blood components (e.g., plasma, , peripheral blood stem cells, etc.) within 90 days prior to the first dose;
  9. Individuals who used any drugs that alter hepatic enzyme activity within 30 days prior to the first dose (e.g., inducers such as barbiturates, carbamazepine, phenytoin sodium, dexamethasone; inhibitors such as selective serotonin reuptake inhibitors [SSRIs], ciprofloxacin, diltiazem, macrolides, metronidazole, ketoconazole, verapamil, fluoroquinolones, etc.), or non-steroidal anti-inflammatory drugs (NSAIDs) (e.g., aspirin, ibuprofen, naproxen, etc.);
  10. Use of any medications (including prescription drugs, over-the-counter drugs, and herbal medicines) and health supplements within 14 days prior to the first dose or within 5 half-lives of previous medication (whichever is longer), with the exception of topical medications and ophthalmic drops intended for local use.
  11. Study participants who have been vaccinated within 30 days prior to the first dose or plan to be vaccinated within 30 days after the end of the study;
  12. Participation in any clinical study within 90 days prior to the first dose;
  13. History of drug abuse within 5 years prior to screening, and/or use of illicit drugs within 90 days prior to screening, and/or history of drug dependence, including herbal medicine, or positive urine drug screening;
  14. Average daily smoking of more than 5 cigarettes within 90 days prior to screening, or unwillingness to avoid using any tobacco products within 48 h prior to the first dose and during hospitalization, or positive result in nicotine screening;
  15. Regular alcohol consumption within 180 days prior to screening, defined as consuming more than 14 units of alcohol per week (1 unit of alcohol = 360 mL of beer or 45 mL of spirits or 150 mL of wine), or unwillingness to stop alcohol intake within 48 h prior to the first dose and during hospitalization, or positive result in alcohol breath test;
  16. Excessive daily consumption of tea, coffee, and/or caffeine-containing beverages (more than 8 cups, 1 cup = 250 mL) within 90 days prior to screening, or unwillingness to abstain from tea, coffee, and/or caffeine-containing foods, grapefruit (pomelo) and/or grapefruit juice (pomelo juice), and/or poppy-containing products within 48 h prior to the first dose and during hospitalization;
  17. Individuals who have plans for reproduction (including sperm or egg donation) from the time of signing the until 90 days after the last administration of the product, and/or who do not agree to use effective non-pharmacological methods during the study period;
  18. Individuals unable to adhere to a standardized diet during the study or those with lactose intolerance (e.g., experiencing diarrhea after consuming milk);
  19. Individuals with difficulty in venous blood collection (intolerance to venipuncture, history of needle or blood phobia, poor vascular condition, etc.);
  20. Individuals who are otherwise unable to complete the study or are deemed unsuitable for inclusion by the investigator shall also be excluded.

    In addition to the aforementioned criteria, female participants meeting any of the following conditions shall also be excluded:

  21. Currently pregnant or breastfeeding, or have a positive pregnancy test result;
  22. Use of oral contraceptives within 30 days prior to the first dose;
  23. Use of long-acting estrogen and/or progestin injections and/or implants within 180 days prior to the first dose;
  24. Unprotected sexual intercourse with a partner within 14 days prior to the first dose.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Huperzine A Oral Solution

    Healthy participants receive multiple escalating oral doses of huperzine A oral solution in sequential cohorts. Advancement to subsequent dose cohorts is gated by review from the Safety Monitoring Committee (SMC) and Sponsor. Subjects within each cohort are randomized to study drug or placebo.

    Drug: Huperzine A Oral Solution

  • Placebo comparator
    Placebo

    Healthy participants receive matching placebo oral solution for multiple-dose administration. Randomization to placebo occurs within each sequential dose cohort, following SMC-gated cohort progression rules.

    Drug: Placebo

Interventions

  • Investigational huperzine A oral solution, administered orally in 4 sequential escalating multiple-dose cohorts to healthy adult participants.

  • DrugPlacebo

    Matching placebo, identical in appearance, taste and packaging to huperzine A oral solution, administered orally for multiple doses.

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability Assessments

    Assess safety and tolerability by evaluating treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and clinically significant abnormal findings from vital signs, physical examinations, 12-lead ECG (QTcF, PR interval, QRS duration, RR interval), and clinical laboratory tests.

    Time frame: From first study drug administration through Day 9

Secondary outcomes

  1. Time to Peak Plasma Concentration (Tmax)

    Time frame: Day 1 and Day 7

  2. Peak Plasma Concentration (Cmax)

    Time frame: Day 1 and Day 7

  3. Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUC0-t)

    Time frame: Day 1 and Day 7

  4. Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUC0-∞)

    Time frame: Day 1 and Day 7

  5. Area Under the Plasma Concentration-Time Curve Over One Dosing Interval (AUC0-τ)

    Time frame: Day 1 and Day 7

  6. Percentage of Area Under the Curve Extrapolated to Infinite Time (AUC_%Extrap)

    Time frame: Day 1 and Day 7

  7. Apparent Volume of Distribution Based on Terminal Phase (Vz/F)

    Time frame: Day 1 and Day 7

  8. Apparent Total Clearance Based on Terminal Phase (CLz/F)

    Time frame: Day 1 and Day 7

  9. Terminal Elimination Rate Constant (λz)

    Time frame: Day 1 and Day 7

  10. Terminal Elimination Half-Life (t1/2)

    Time frame: Day 1 and Day 7

  11. Mean Residence Time From Time Zero to Last Quantifiable Concentration (MRT0-t)

    Time frame: Day 1 and Day 7

  12. Mean Residence Time From Time Zero Extrapolated to Infinite Time (MRT0-∞)

    Time frame: Day 1 and Day 7

  13. Steady-State Trough Plasma Concentration (Cmin,ss)

    Time frame: Day 7

  14. Steady-State Average Plasma Concentration Over One Dosing Interval (Cav,ss)

    Time frame: Day 7

  15. Steady-State Peak-to-Trough Swing Factor (Swing)

    Time frame: Day 7

  16. Steady-State Peak-to-Trough Degree of Fluctuation (DF)

    Time frame: Day 7

  17. Accumulation Ratio Based on Peak Plasma Concentration (Rcmax)

    Time frame: Day 1 and Day 7

  18. Accumulation Ratio Based on Area Under Curve Over One Dosing Interval (RAUC)

    Time frame: Day 1 and Day 7

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2026; primary completion for Dec 2026, 4 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2026
First posted
Aug 25, 2026
StartEst.
Aug 25, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Aug 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07784335
Lead sponsor
Wanbangde Pharmaceutical Group Co., LTD
Responsible party
Sponsor
First posted
Aug 25, 2026
Start date
Aug 25, 2026 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Aug 25, 2026

Study contacts

Juan Li
Contact
lijuan@wepon.cn
+8613735826039

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Huperzine A

Start the discussion